Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsReview Published on 2021-05-062022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI adenovirus-vectored COVID-19 vaccine Adenovirus-vectored vaccine adverse effect Antigen arthralgia clinical clinical feature clinical trial collected Control COVID-19 COVID-19 vaccine database datasets diarrhea domain dose doses Efficacy extreme highest immune responses injection Injections lowest Meta-analysis mRNA-based mRNA-based vaccine Placebo randomized clinical trial RBD RCT RCTs reported review robust Safety SARS-CoV-2 searched Side effect Side effects stimulated systemic and local the vaccine Vaccine Vaccines [DOI] 10.3390/vaccines9050467 PMC 바로가기 [Article Type] Review
An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults건강한 필리핀 성인에서 장티푸스 결합 백신(Vi-CRM197)의 안전성과 면역원성을 평가하기 위한 공개 라벨, 비교, 단일 용량, 임상 1상 연구Article Published on 2021-05-062024-08-21 Journal: Vaccine [Category] 살모넬라증, [키워드] Conjugate vaccine immunogenicity Safety Typbar-TCV® typhoid Vi-CRM197. [DOI] 10.1016/j.vaccine.2021.03.089
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter StudyOriginal Article Published on 2021-05-062024-09-04 Journal: Journal of Korean medical science [Category] 대상포진, [키워드] chronic hepatitis C direct-acting antiviral Effectiveness Safety [DOI] 10.3346/jkms.2021.36.e142 PMC 바로가기 [Article Type] Original Article
Clinical use of Jak 1 inhibitors for rheumatoid arthritisSupplement Papers Published on 2021-05-052024-09-04 Journal: Rheumatology (Oxford, England) [Category] 대상포진, [키워드] Efficacy filgotinib Jak 1 selectivity Safety Upadacitinib [DOI] 10.1093/rheumatology/keab265 PMC 바로가기 [Article Type] Supplement Papers
The safety of JAK-1 inhibitorsJAK-1 억제제의 안전성Review Published on 2021-05-052023-06-01 Journal: Rheumatology (Oxford, England) [Category] Fulltext, 대상포진, 두창, 수두, 홍역, [키워드] JAK inhibitor pharmacovigilance rheumatoid arthritis Safety trials Zoster [DOI] 10.1093/rheumatology/keaa895 PMC 바로가기 [Article Type] Review
Depressive Symptomatology and Practice of Safety Measures among Undergraduate Students during COVID-19: Impact of GenderArticle Published on 2021-05-052022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] affected age Analysis association center chi-square test conducted COVID-19 COVID-19 pandemic cross-sectional Depression depressive symptom Depressive symptoms distress effective eight elevated female Gender Impact independent indicated male mean value measure Multiple linear regression outbreak participant Practice precautionary measures Prevalence prevalent problem Protective psychological health reducing reduction Regression reported Research Result risk Safety Saudi Arabia scale Spearman’s correlation student suggested Symptom Symptomatology Symptoms university undergraduates was performed were assessed [DOI] 10.3390/ijerph18094924 PMC 바로가기 [Article Type] Article
Vaccine safety – is the SARS-CoV-2 vaccine any different?백신 안전성 - SARS-CoV-2 백신은 다른가요?Review Published on 2021-05-042022-09-11 Journal: Human vaccines & immunotherapeutics [Category] SARS, 신약개발, [키워드] adverse effects approval approved changed clinically COVID-19 COVID-19 pandemic drug effective FDA food infections morbidity morbidity and mortality reducing Research Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 vaccine the SARS-CoV-2 Vaccine Vaccines VAERS [DOI] 10.1080/21645515.2020.1829414 PMC 바로가기 [Article Type] Review
Anesthesia Management and Perioperative Infection Control in Patients With the Novel CoronavirusReview Published on 2021-05-012023-07-13 Journal: Journal of cardiothoracic and vascular anesthesia [Category] SARS, [키워드] Anesthesia COVID-19 Infection Safety [DOI] 10.1053/j.jvca.2020.03.035 PMC 바로가기 [Article Type] Review
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial비활성화된 SARS-CoV-2 백신 BBV152의 안전성 및 면역원성: 이중 맹검, 무작위, 1상 시험Clinical Trial Published on 2021-05-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단, 치료기술, [키워드] 95% CI Administered adverse event Adverse reactions alum assigned baseline Bharat block Block randomisation CD4 CD8 Cell-mediated responses control group control vaccine COVID-19 doses double-blind Effect Efficacy eligible ELISPOT enrolled evaluated event fatigue Fever first dose groups headache healthy hospital immune responses immunogenicity inactivated India individual injection site pain intramuscular dose investigator investigators Local Mild mitigate moderate multicentre nausea neutralisation nine nucleic acid outcome participant Participants Phase 1 phase 1 trial Phase 2 platform Pneumonitis positive Primary outcomes randomisation randomised Randomly receive Registered reported response Safety SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine screened secondary secondary outcome selected Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rates serology test serology tests Seven staining study duration subset systemic adverse reaction systemic adverse reactions systemic reactogenicity T-cell Response T-cell responses the vaccine tolerable Toll-like receptor treatment group Trial trials vaccination Vaccine Viral vomiting was done were excluded wild-type virus [DOI] 10.1016/S1473-3099(20)30942-7 PMC 바로가기 [Article Type] Clinical Trial
A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis렘데시비르 치료(SORT) 간격이 짧을수록 중등도에서 중증 COVID-19의 사망률이 낮아집니다. 실제 분석Article Published on 2021-05-012022-09-11 Journal: International Journal of Infectious Diseases [Category] 치료법, 치료제, [키워드] 350 patient 350 patients 95% CI all-cause mortality Analysis analyzed Anti-viral treatment benefit Care conducted COVID COVID-19 death Earlier initiation Efficacy evaluated Final final analysis In-hospital India lower mortality moderate-to-severe COVID-19 Mortality Odds ratio outcome Patient patients died Remdesivir Retrospective study Safety severe significantly lower subgroups symptom onset therapy treated Treatment [DOI] 10.1016/j.ijid.2021.02.092 PMC 바로가기 [Article Type] Article